Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib Trial of ITR-251 in Advanced Solid Tumors and mCRPC
NCT07870096Phase 1Not yet recruiting
- Sponsor
- Iteria Biopharma
- Start
- Oct 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of ITR-251 in solid tumor and metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Iteria Biopharma. Primary endpoints: Recommended Phase 2 Dose at 28 days and Treatment-emergent adverse events at 12 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ITR-251
03
Conditions
solid tumormetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07870096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07870096.